Selling, General, and Administrative Costs: AbbVie Inc. vs Veracyte, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals and diagnostics, understanding the financial health of companies is crucial. This chart provides a fascinating comparison of Selling, General, and Administrative (SG&A) expenses between AbbVie Inc. and Veracyte, Inc. from 2014 to 2023. AbbVie, a giant in the pharmaceutical industry, has seen its SG&A expenses grow by approximately 66% over this period, peaking in 2022. In contrast, Veracyte, a smaller player in the diagnostics field, has experienced a more modest increase of around 350%, reflecting its growth trajectory. Despite the vast difference in scale, with AbbVie's expenses being nearly 100 times greater than Veracyte's, both companies show a commitment to strategic spending. This data highlights the dynamic nature of the healthcare sector, where both established giants and emerging innovators navigate their financial landscapes.